

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number  
WO 01/28557 A1

(51) International Patent Classification<sup>2</sup>: A61K 31/405, 31/405, C07D 209/12 (74) Agents: YALE, Guy, D. et al.; Alix, Yale & Ristas, LLP, 750 Main Street, Hartford, CT 06103 (US).

(21) International Application Number: PCT/US00/28832

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 18 October 2000 (18.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/159,997 18 October 1999 (18.10.1999) US

(71) Applicant (for all designated States except US): UNIVERSITY OF CONNECTICUT [US/US]; 263 Farmington Avenue, Farmington, CT 06032 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): MAKRIYANNIS, Alexandros [US/US]; 348G Foster Drive, Willimantic, CT 06226 (US). DENG, Hongfeng [CN/US]; Apt. 64, 1 Northwood Road, Storrs, CT 06268 (US).

WO 01/28557 A1

(54) Title: CANNABIMIMETIC INDOLE DERIVATIVES

(57) Abstract: Novel cannabimimetic indole derivatives are presented which have preferentially high affinities for one of the cannabinoid CB1 or CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.

## CANNABIMIMETIC INDOLE DERIVATIVES

### Field of the Invention

5 The present invention relates generally to cannabinoid analogs and is more particularly concerned with new and improved indole cannabinoid analogs exhibiting high binding affinities for cannabinoid receptors, pharmaceutical preparations employing these analogs and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.

10

### Background of the Invention

15 Classical cannabinoids such as the marijuana derived cannabinoid  $\Delta^9$ -tetrahydrocannabinol, ( $\Delta^9$ -THC) produce their pharmacological effects via interaction with specific cannabinoid receptors in the body. So far, two cannabinoid receptors have been characterized: CB1, a central receptor found in the mammalian brain and peripheral tissues and CB2, a peripheral receptor found only in the peripheral tissues. Compounds that are agonists or antagonists for one or both of these receptors have been shown to provide a variety of pharmacological effects. See, for example, Pertwee, R.G., Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol. Ther., (1997) 74:129 - 180 and

20 Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L., Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, Trends Neurosci. (1998) 21:521 - 528.


25 There is considerable interest in developing cannabinoid analogs possessing high affinity for one of the CB1 or CB2 receptors and/or metabolic stability. Such analogs may offer a rational therapeutic approach to a variety of disease states. One class of cannabimimetic analogs encompasses indole derivatives such as the well known aminoalkylindoles represented by WIN 55212-2 {(R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-*de*]-1,4-benzoxazin-6-yl](1-naptha-1-yl)methanone}. Aminoalkylindoles of this type typically have a carbon linked alkylheterocyclic substituent at the indole-1 position, which is believed to be important for their cannabimimetic activities.

These known materials are not selective for preferential activation of one of the CB1 or CB2 receptors.

#### Summary of the Invention

5 Aminoalkylindoles have been found to act as agonists for the CB1 and CB2 receptors and occasionally as antagonists for the CB1 and CB2 receptors. The invention includes compounds selective for either the CB1 or CB2 receptors. Further, some of the compounds have agonistic or antagonistic properties.

10 One aspect of the invention includes several novel aminoalkylindole cannabinoid analogs and physiologically acceptable salts thereof. In one embodiment of the invention, straight carbon chains were introduced to the indole-1 position. Different functional groups were also introduced to the straight carbon chains. This embodiment is shown as A.



20 Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of nitro; nitroso; amino; alkylamino; dialkylamino; azido ( $N_3$ ); cyano; isothiocyanato and phenyl.

X is selected from the group consisting of halogen; hydrogen; hydroxy; low alkanoate; formyl; amino; cyano; isothiocyanato and azido.

25 R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms; saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms; cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms; bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms; and heterocyclic rings interconnected to the indole-1 position with one or two carbon atoms.

$R_2$  is selected from the group consisting of H and lower alkyl.


$Y$  is selected from the group consisting of carbonyl and  $CH=CH$  (cis or trans).

$R_3$  is selected from the group consisting of phenyl; napthyl; 9-anthracenyl; 5 phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato; napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato; and 9-anthracenyl with no more than two substituents selected 10 from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.

The analogs of this embodiment show high binding affinities for the CB1 and CB2 cannabinoid receptors. More importantly, some of these compounds 15 show not only comparable cannabimimetic activity with the compound WIN 55212-2 but also a surprisingly higher selectivity for one of the CB1 or CB2 receptors. More specifically, the inventive analogs showed similar or higher receptor binding affinity than the well-known indole cannabinoid WIN 55212-2.

Another embodiment of the invention is shown as B. In this embodiment 20 the functionalities of the novel cannabimimetic indole analogs were modified in the indole-3 and/or indole-6 positions.

25



B

$Z$  may be in the 4-, 5-, 6- or 7- position and is selected from the group 30 consisting of halogen; hydroxy; methoxy and lower alkyl.

$X$  is selected from the group consisting of hydrogen; hydroxy; lower

alkanoate; formyl; amino; cyano and isothiocyanato.

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms; saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms; cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms; and bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms.

R<sub>2</sub> is selected from the group consisting of H and lower alkyl.

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans).

R<sub>3</sub> is selected from the group consisting of phenyl; napthyl; 9-anthracyl; phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato; napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, and 9-anthracyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.

The analogs of this embodiment are surprisingly potent cannabimimetic compounds with high CB1 and/or CB2 selectivity.

Since CB2 selective cannabinoids are able to activate the CB2 receptor and thereby modulate the immune system with little psychoactivity or other CNS effects, these analogs are possible therapeutic agents. Additionally, some of the iodide and fluoride containing analogs are potential radioactive probes for imaging *in vivo* the distribution of cannabinoid receptors. The azido modified analogs are excellent affinity probes for characterizing binding pockets of cannabinoid receptors.

The analogs disclosed herein are relatively easy to manufacture. Additionally these analogs have better physiochemical properties than naturally occurring cannabinoids. Thus, the novel cannabimimetic indole derivatives

described herein, and physiologically acceptable salts thereof, represent potentially useful materials for providing a physiological effect to treat pain, peripheral pain, glaucoma, epilepsy, nausea such as associated with cancer chemotherapy, AIDS Wasting Syndrome, cancer, neurodegenerative diseases 5 including Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, mental disorders such as Schizophrenia and depression; to prevent or reduce endotoxic shock and hypotensive shock; to modulate appetite; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to prevent or reduce inflammation; to provide 10 neuroprotection and to effect memory enhancement.

The novel cannabimimetic indole derivatives described herein also provide useful materials for testing the cannabinoid system. Thus, another aspect of the invention is the administration of a therapeutically effective amount of an inventive compound, or a physiologically acceptable salt thereof, to an individual 15 or animal to provide a physiological effect.

#### Description of Some Preferred Embodiments

As used herein, a "therapeutically effective amount" of a compound, is the quantity of a compound which, when administered to an individual or animal, 20 results in a sufficiently high level of that compound in the individual or animal to cause a discernible increase or decrease in stimulation of cannabinoid receptors.

Physiological effects that result from cannabinoid receptor stimulation include analgesia, decreased nausea resulting from chemotherapy, sedation and increased appetite. Other physiological functions include relieving intraocular 25 pressure in glaucoma patients and suppression of the immune system. Typically, about 10 mg/day to about 1,000 mg/day is a possible "therapeutically effective amount" for the inventive compounds.


As used herein, an "individual" refers to a human. An "animal" refers to, for example, veterinary animals, such as dogs, cats, horses and the like, and 30 farm animals, such as cows, pigs and the like.

The compound of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include, for example, saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.

The inventive cannabinoid analogs are generally described by the structural formulas previously disclosed. The following examples are given for purposes of illustration only in order that the present invention may be more fully understood. These examples are not intended to limit in any way the practice of the invention. The prepared cannabimimetic indole derivatives can generally be described with reference to structural formulas 1 and 2 below and include physiologically acceptable salts thereof.

The inventive cannabimimetic indole derivatives of structural formula 1 include both racemics and two enantiomers.

25



structural formula 1

30

Z is in the indole-6 position and is selected from the group consisting of

H; NO<sub>2</sub>; NH<sub>2</sub>; N<sub>3</sub> and NCS.

R<sub>1</sub> is a heterocyclic ring interconnected to the indole-1 position with one carbon atom.

X is hydrogen.

5 R<sub>2</sub> is selected from the group consisting of H and methyl.

Y is carbonyl.

R<sub>3</sub> is selected from the group consisting of phenyl; napthyl; adamantanyl; pyrenyl and substituted versions of any of the above.

The inventive materials of structural formula 1 are listed in TABLE 1. It should be noted that R<sub>1</sub> for all of the materials of TABLE 1 was 1-(N-Methyl-2-piperidinyl)methyl. All of the materials of TABLE 1 have a chiral center and the binding affinities of the materials of TABLE 1 were obtained by evaluating their racemic samples.


TABLE 1

analog	Z	R <sub>2</sub>	R <sub>3</sub>	K <sub>1</sub> nM	
				CB1	CB2
AM664	NO <sub>2</sub>	CH <sub>3</sub>	2-iodophenyl	40	80.0
AM665	NH <sub>2</sub>	CH <sub>3</sub>	2-iodophenyl	206	20.3
AM671	N <sub>3</sub>	CH <sub>3</sub>	Phenyl	155	59.1
AM684	NCS	CH <sub>3</sub>	Phenyl	181	44.8
AM1215	N <sub>3</sub>	CH <sub>3</sub>	2-iodophenyl	40.7	21.9
AM1216	NCS	CH <sub>3</sub>	2-iodophenyl	210	25.2
AM2209	N <sub>3</sub>	H	5-azido-2-iodophenyl	48.8	41.8
AM2223	NCS	H	5-isothiocyanato-2-iodophenyl	64.8	29.9
AM1221	NO <sub>3</sub>	CH <sub>3</sub>	1-naphthyl	52.3	0.28
AM1225	NH <sub>3</sub>	CH <sub>3</sub>	1-naphthyl	439.6	38.5
AM1231	N <sub>3</sub>	CH <sub>3</sub>	1-naphthyl	31.2	34.2
AM1218	NO <sub>2</sub>	H	1-naphthyl	11.2	3.98
AM1219	NH <sub>2</sub>	H	1-naphthyl	96.6	31.3
AM1224	N <sub>3</sub>	H	1-naphthyl	20.2	0.73
AM1217	NCS	H	1-naphthyl	255	81.5
AM1299	H	H	4-nitro-1-naphthyl	12.4	13.5
AM1296	H	H	1-naphthyl	7.57	3.88
AM1220	H	H	1-naphthyl	3.88	73.4
AM2212	N <sub>3</sub>	H	4-iodo-1-naphthyl	31.0	2.90
AM2215	NCS	H	4-isothiocyanato-1-naphthyl	235	99.6
AM1248	H	H	adamantanyl	100	332

TABLE 1

analog	Z	R <sub>2</sub>	R <sub>3</sub>	K <sub>1</sub> nM	
				CB1	CB2
AM1253	H	H	2-pyrenyl	60.3	126

5



structural formula 2

10 Z is in the indole-6 position and is selected from the group consisting of hydrogen; NO<sub>2</sub>; NH<sub>2</sub> and halogen.

X is selected from the group consisting of halogen; H; OH; OCOCH<sub>3</sub>; OTs; NCS; OAc and CN.

15 R<sub>1</sub> is a saturated lower alkane with a maximum length of seven carbon atoms.

R<sub>2</sub> is selected from the group consisting of H and methyl.

Y is carbonyl.

R<sub>3</sub> is selected from the group consisting of phenyl; napthyl; and substituted versions of any of the above.

20 The inventive materials of structural formula 1 are listed in TABLE 2. R<sub>1</sub> lists the number of carbon atoms in the chain at that position.

TABLE 2

analog	Z	R <sub>1</sub>	X	R <sub>2</sub>	R <sub>3</sub>	K <sub>i</sub> nM	
						CB1	CB2
AM683	H	4	H	CH <sub>3</sub>	2-iodophenyl	272	281
AM669	H	5	H	CH <sub>3</sub>	2-iodophenyl	47.2	38.6
AM682	H	6	H	CH <sub>3</sub>	2-iodophenyl	332	693
AM672	H	7	H	CH <sub>3</sub>	2-iodophenyl	1603	1511
AM689	H	5	OCOCH <sub>3</sub>	CH <sub>3</sub>	2-iodophenyl	2279	1019
AM690	H	5	OH	CH <sub>3</sub>	2-iodophenyl	4850	1972
AM2227	H	5	OTs	CH <sub>3</sub>	2-iodophenyl	1024	2968
AM2229	H	5	I	CH <sub>3</sub>	2-iodophenyl	116.5	46.2
AM2230	H	5	NCS	CH <sub>3</sub>	2-iodophenyl	195	29.5
AM2225	H	5	F	CH <sub>3</sub>	2-iodophenyl	5.97	3.8
AM679	H	5	H	H	2-iodophenyl	13.5	49.5
AM692	H	5	OCOCH <sub>3</sub>	H	2-iodophenyl	2656	1519
AM693	H	5	OH	H	2-iodophenyl	835	526
AM697	H	5	OTs	H	2-iodophenyl	1306	1116
AM698	H	5	I	H	2-iodophenyl	135.8	314.7
AM1201	H	5	NCS	H	2-iodophenyl	106	110
AM694	H	5	F	H	2-iodophenyl	0.08	1.44
AM1202	H	5	H	H	2-iodo-5-nitrophenyl	98.9	22.9
AM1203	H	5	H	H	2-iodo-5-aminophenyl	63.6	88.9
AM1204	H	5	H	H	2-iodo-5-isothiocyanophenyl	5659	3353
AM1205	H	5	H	H	2-iodo-5-azidophenyl	116.9	195.7
AM1206	H	5	H	H	2,5-diiodophenyl	105.1	150.5
AM1284	H	3	OCOCH <sub>3</sub>	H	1-naphthyl	126.8	102.8
AM1289	H	3	OTs	H	1-naphthyl	359.6	78.64
AM1292	H	3	I	H	1-naphthyl	3.1	18.1
AM1294	H	3	NCS	H	1-naphthyl	283.3	237.3
AM1282	H	4	OCOCH <sub>3</sub>	H	1-naphthyl	133.4	100.8
AM1283	H	4	OH	H	1-naphthyl	117.2	196.5
AM1286	H	4	OTs	H	1-naphthyl	1509	1289
AM1288	H	4	I	H	1-naphthyl	1.3	10.5
AM1291	H	4	NCS	H	1-naphthyl	2958	1804
AM1295	H	4	F	H	1-naphthyl	2.5	30.7
AM2232	H	4	CN	H	1-naphthyl	0.28	1.48
AM2231	NO <sub>2</sub>	4	CN	H	1-naphthyl	4.90	23.9
AM2202	H	5	OH	H	1-naphthyl	33.1	110.6
AM2203	H	5	I	H	1-naphthyl	7.8	45.8

TABLE 2

analog	Z	R <sub>1</sub>	X	R <sub>2</sub>	R <sub>3</sub>	K <sub>i</sub> nM	
						CB1	CB2
AM2204	H	5	NCS	H	1-naphthyl	7.5	24.4
AM2201	H	5	F	H	1-naphthyl	1.0	2.6
AM1233	NO <sub>2</sub>	5	OAc	H	1-naphthyl	141.7	153.9
AM1234	NO <sub>2</sub>	5	OH	H	1-naphthyl	77.6	196.8
AM1235	NO <sub>2</sub>	5	F	H	1-naphthyl	1.5	20.4
AM1236	NH <sub>2</sub>	5	OAc	H	1-naphthyl	1127	558.8
AM1237	NH <sub>2</sub>	5	OH	H	1-naphthyl	836.8	244.4
AM1238	I	5	OH	H	1-naphthyl	3.1	17.3
AM1230	I	5	F	H	1-naphthyl	1.1	2.4
AM2210	H	4	I	H	4-nitro-1-naphthyl	1.8	11.3
AM2213	H	4	I	H	4-azido-1-naphthyl	3.0	30
AM2216	H	4	I	H	4-isothiocyanato-1-naphthyl	42.4	213
AM1256	H	5	H	CH <sub>3</sub>	4-dimethylamino-1-naphthyl	4.74	18.6


The above materials were generally prepared as follows.

A. General Preparation procedures for materials listed in Table 2

The materials listed in Table 2 can be prepared by methods outlined in Scheme 1.

5


Scheme 1



When  $\text{Z} = \text{NO}_2$ , the structures can be transformed to the different substituents as listed in Table 2 using methods outlined in Scheme 2.


10

Scheme 2




5 The commercially unavailable R3-COCl used in Scheme 1 can be prepared according to Scheme 3.

Scheme 3



10 After these acid chlorides were connected to indole 3-position, the nitro group in them can be further transformed into amino, iodo, azido, and isothiocyanate groups according to the methods outlined in Scheme 4.

Scheme 4

B. General preparation procedures for materials listed in Table 1

5 These materials can be prepared in similarly manners as those compounds listed in Table 2 by using N-methyl-2-piperidinemethyl chloride instead of acetoxyalkylhalides for the alkylation of indole 1-position in Scheme 1.

10 Examples of specific analogs were prepared as follows:

15 **3-Acyl-1*H*-indole.** 17.5 ml of a 3M solution of methyl magnesium bromide in ethyl ether was added dropwise with stirring to a solution of indole (5.85 g, 50 mmol) in 50 mL of ethyl ether at 0 °C. After addition, the reaction mixture was warmed up to room temperature and stirred for 2 hours (h). Then the reaction mixture was cooled down again to 0 °C and to it was added slowly with violent stirring a solution of acyl chloride (50 mmol) in 50 mL of ethyl ether. The resulting reaction mixture was warmed up to room temperature and stirred for another 1 h followed by the slow addition of 375 ml of ammonium chloride aqueous solution. After violently stirring for 30 min, a white solid was formed and filtrated. The filtrate was washed successively with ethyl ether and recrystallized from ethyl acetate:hexane to afford the product.

2-methyl-3-acyl-1*H*-indole. The foregoing procedure was repeated using 2-methyl indole in place of indole.

5       1-Alkyl-2-methyl-3-acyl-1*H*-indole. To a 1.2 mmol suspension of sodium hydride (48 mg, 60% in mineral oil) in 2 mL of dimethylformamide (DMF) was added 2-methyl-3-acyl-1*H*-indole (0.4 mmol). After stirring at room temperature for 30 min, alkyl bromide (0.6 mmol) was added dropwise. The resulting mixture was heated to 65 °C and stirred for 3 h followed by removal of solvent under 10 vacuum. The residue was separated by flash column chromatography (silica gel, petroleum ether-ethyl acetate, 5:1, v/v) to afford the product.

A person of ordinary skill in the art, understanding the disclosures for the general preparation and specific preparation examples would know how to modify the disclosed procedures to achieve the above listed analogs.

15       The materials were tested for CB2 receptor binding affinity and for CB1 receptor affinity (to determine selectivity for the CB2 receptor). As used herein, "binding affinity" is represented by the IC<sub>50</sub> value which is the concentration of an analog required to occupy the 50% of the total number (B<sub>max</sub>) of the receptors. The lower the IC<sub>50</sub> value the higher the binding affinity. As used 20 herein an analog is said to have "binding selectivity" if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has an IC<sub>50</sub> of 0.1 nM for CB1 and 10 nM for CB2, is 100 times more selective for the CB1 receptor. The binding affinities (K<sub>i</sub>) are expressed in nanomoles (nM) and are listed in TABLE 1 and TABLE 2 above.

25       For the CB1 receptor binding studies, membranes were prepared from rat forebrain membranes according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 107 - 118 (1981). The binding of the novel analogues to the CB1 cannabinoid receptor was assessed as described in W.A. Devane et al, Determination and Characterization of a Cannabinoid Receptor in a Rat Brain, Mol. Pharmacol., 34, 605 - 613 (1988) and A. Charalambous et al, 5'-azido Δ<sup>8</sup>-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor, J. Med. Chem., 30

35, 3076 - 3079 (1992) with the following changes. The above articles are incorporated by reference herein.

5       Membranes, previously frozen at -80°C, were thawed on ice. To the stirred suspension was added three volumes of TME (25mM Tris-HCl buffer, 5 mM MgCl<sub>2</sub> and 1 mM EDTA) at a pH 7.4. The suspension was incubated at 4°C for 30 min. At the end of the incubation, the membranes were pelleted and washed three times with TME.

10      The treated membranes were subsequently used in the binding assay described below. Approximately 30 µg of membranes were incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [<sup>3</sup>H] CP-55,940, and various concentrations of test materials at 200 °C for 1 hour. The samples were filtered using Packard Filtermate 196 and Whatman GF/C filterplates and washed with wash buffer (TME) containing 0.5% BSA. Radioactivity was detected using 15     MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding for [<sup>3</sup>H] CP-55,940, 20     determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC<sub>50</sub> values. Data from at least two independent experiments performed in duplicate was used to calculate IC<sub>50</sub> values which were converted to K<sub>i</sub> values using the assumptions 25     of Cheng et al, Relationship Between the Inhibition Constant (K<sub>i</sub>) and the concentration of Inhibitor which causes 50% Inhibition (IC<sub>50</sub>) of an Enzymatic Reaction, Biochem. Pharmacol., 22, 3099-3102, (1973), which is incorporated by reference herein.

30      For the CB2 receptor binding studies, membranes were prepared from frozen mouse spleen essentially according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981) which is incorporated by

reference herein. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption. The CB2 binding assay was conducted in the same manner as for the CB1 binding assay. The binding affinities ( $K_i$ ) were also expressed in nanomoles (nM).

5        The physiological and therapeutic advantages of the inventive materials can be seen with additional reference to the following references, the disclosures of which are hereby incorporated by reference. Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. Colombo G, Agabio R, Diaz G. et al: Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. (1998) 63-PL13-PL117. Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181.

10      Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998) 13:871-876. Terranova J-P, Storme J-J Lafon N et al: Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psycho-pharmacol (1996) 126:165-172. Hampson AL Grimaldi M. Axirod J.

15      Wink D: Cannabidiol and (-)  $\Delta^9$  tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl Acad Sci. USA (1998) 95:8268-8273. Buckley NE, McCoy KI, Mpzey E et al Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB<sub>2</sub> receptor. Eur. J Pharmacol (2000) 396:141-149. Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997). Joy JE, Wagtson SJ, Benson JA: Marijuana and Medicine Assessing the Science Base. National Academy Press, Washington, DC, USA (1999). Shen M. Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.

20      DePetrocellis L, Melck D, Palmisano A. et al: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl. Acad. Sci USA (1998) 95:8375-8380. Green K. Marijuana smoking vs. cannabinoids for

25

30

glaucoma therapy. Arch. Ophibalmol. (1998) feb 433-1437. Hemming M, Yellowlees PM, Effective treatment of Tourette's syndrome with marijuana. J. Psychopharmacol, (1993) 7:389-391. Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195. Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. Consroe P, Musty R, Rein J, Tillary W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis, Eur. Neurol. (1997) 38-44-48. Pinnegan-Ling D, Musty R. Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53. Brenneisen R, Pgli A, Elsohly MA, Henn V, Spiess Y: The effect of orally and rectally administered  $\Delta^9$ -tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet (1995) 345:579. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990), Z40:1-4. Herzberg U, Eliav E, Bennett GJ, Kopin IJ: The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rare model of neuropathic pain. Neurosci. Letts. (1997) 221:157-160. Richardson JD, Kilo S, Hargreaves KM, Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 75:111-119. Richardson JD, Aanonsen I, Hargreaves KM: Antihyperalgesic effects of a spinal cannabinoids. Eur. J. Pharmacol. (1998) 346:145-153. Calignano A, La Rana G, Diuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394:277-291. Wagner JA, Varga K, Jarai Z, Kunos G: Mesenteric vasodilation mediated by endothelia anandamide receptors. Hypertension (1999) 33:429-434. Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a.

30 As can be seen from the results in the TABLES, some of the compounds, for example, AM1295, AM1235, AM1288 and AM694, show a high selectivity


for the CB1 receptor. Other compounds, for example, AM2230, AM1289, and AM1237, show a high selectivity for the CB2 receptor. The inventive analogs described herein, and physiologically acceptable salts thereof, have high potential when administered in therapeutically effective amounts for providing a physiological effect useful to treat pain, peripheral pain, glaucoma, epilepsy, nausea such as associated with cancer chemotherapy, AIDS Wasting Syndrome, cancer, neurodegenerative diseases including Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, mental disorders such as Schizophrenia and depression; to prevent or reduce endotoxic shock and hypotensive shock; to modulate appetite; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to prevent or reduce inflammation; to provide neuroprotection and to effect memory enhancement. Thus, another aspect of the invention is the administration of a therapeutically effective amount of an inventive compound, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological effect.

In addition, some of the iodide and fluoride containing compounds, for example, AM694 and AM1230, are potential radioactive probes which would be useful for imaging *in vivo* the distribution of cannabinoid receptors. Further, azido containing compounds, for example, AM2212, AM2213 and AM1224, would be useful as affinity probes for characterizing binding pockets of cannabinoid receptors.

Those skilled in the art will recognize, or be able to ascertain with no more than routine experimentation, many equivalents to the specific embodiments of the invention disclosed herein. Such equivalents are intended to be encompassed by the scope of the invention.

**What Is Claimed Is:**

1. A compound of the formula:



and physiologically acceptable salts thereof wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of nitro, nitroso, amino, alkylamino, dialkylamino, azido, cyano, isothiocyanato, and phenyl;

X is selected from the group consisting of halogen; hydrogen; hydroxy, low alkanoate, formyl, amino, cyano, isothiocyanato and azido;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms, saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms, cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, and heterocyclic rings interconnected to the indole-1 position with one or two carbon atoms;

R<sub>2</sub> is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans); and

R<sub>3</sub> is selected from the group consisting of phenyl, napthyl, 9-anthracyanyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato and 9-anthracyanyl with no more than two substituents selected

from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.


2. The compound of claim 1, wherein Z is in the indole-6 position and is selected from the group consisting of H, NO<sub>2</sub>, NH<sub>2</sub> and halogen.

3. The compound of claim 1, wherein Y is C=O.

4. The compound of claim 1, wherein R<sub>1</sub> is an alkane with a maximum length of seven carbon atoms.

5. The compound of claim 1, wherein R<sub>2</sub> is selected from the group consisting of H and CH<sub>3</sub>.

6. A method of stimulating a cannabinoid receptor in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound having the formula:



and physiologically acceptable salts thereof wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of nitro, nitroso, amino, alkylamino, dialkylamino, azido, cyano, isothiocyanato, and phenyl;

X is selected from the group consisting of halogen, hydrogen, hydroxy, low alkanoate, formyl, amino, cyano, isothiocyanato and azido;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms; saturated


or unsaturated branched carbon chains with a maximum length of seven carbon atoms; cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, and heterocyclic rings interconnected to the indole-1 position with one or two carbon atoms;

R<sub>2</sub> is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans); and

R<sub>3</sub> is selected from the group consisting of phenyl, napthyl, 9-anthracyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato and 9-anthracyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.

7. A compound of the formula:



and physiologically acceptable salts thereof wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of halogen, hydroxy, methoxy, and lower alkyl;

X is selected from the group consisting of halogen, hydrogen, hydroxy, lower alkanoate, formyl, cyano, and isothiocyanato;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated

straight carbon chains with a maximum length of seven carbon atoms, saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms, cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms and bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms;

$R_2$  is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and  $CH=CH$  (cis or trans); and

$R_3$  is selected from the group consisting of phenyl, napthyl, 9-anthracenyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, and 9-anthracenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.


8. The compound of claim 7, wherein Z is in the indole-6 position and is selected from the group consisting of H,  $NO_2$ ,  $NH_2$ ,  $N_3$  and NCS.

9. The compound of claim 7, wherein  $R_1$  is  $CH_2$  and X is a heterocyclic structure.

10. The compound of claim 7, wherein Y is  $C=O$ .

11. The compound of claim 7, wherein  $R_2$  is selected from the group consisting of H and  $CH_3$ .

12. A method of stimulating a cannabinoid receptor in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound having the formula:



and physiologically acceptable salts thereof wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of halogen, hydroxy, methoxy, and lower alkyl;

X is selected from the group consisting of halogen, hydrogen, hydroxy, lower alkanoate, formyl, cyano, and isothiocyanato;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms, saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms, cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms and bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms;


R<sub>2</sub> is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans); and

R<sub>3</sub> is selected from the group consisting of phenyl, naphthyl, 9-anthracyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, naphthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, and 9-anthracyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino,

dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.

13. A pharmaceutical preparation containing a therapeutically effective amount of a compound having the formula:



and physiologically acceptable salts thereof wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of nitro, nitroso, amino, alkylamino, dialkylamino, azido, cyano, isothiocyanato, and phenyl;

X is selected from the group consisting of halogen; hydrogen; hydroxy, low alkanoate, formyl, amino, cyano, isothiocyanato and azido;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms, saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms, cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms, and heterocyclic rings interconnected to the indole-1 position with one or two carbon atoms;

R<sub>2</sub> is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans); and

R<sub>3</sub> is selected from the group consisting of phenyl, napthyl, 9-anthracyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino,

alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato and 9-anthracyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato..

14. The pharmaceutical preparation of claim 13 wherein,

Z may be in the 4-, 5-, 6- or 7- position and is selected from the group consisting of halogen, hydroxy, methoxy, and lower alkyl;

X is selected from the group consisting of halogen, hydrogen, hydroxy, lower alkanoate, formyl, cyano, and isothiocyanato;

R<sub>1</sub> is selected from the group consisting of saturated or unsaturated straight carbon chains with a maximum length of seven carbon atoms, saturated or unsaturated branched carbon chains with a maximum length of seven carbon atoms, cyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms and bicyclic aliphatic rings interconnected to the indole-1 position with one or two carbon atoms;

R<sub>2</sub> is selected from the group consisting of H and lower alkyl;

Y is selected from the group consisting of carbonyl and CH=CH (cis or trans); and

R<sub>3</sub> is selected from the group consisting of phenyl, napthyl, 9-anthracyl, phenyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, napthyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato, and 9-anthracyl with no more than two substituents selected from the group consisting of halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and isothiocyanato.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/28832

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/405, 31/4045; C07D 209/12  
US CL : 514/419; 548/491, 494

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/419; 548/491, 494

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y - A	YAMADA et al. Aminoalkyl-indole Isothiocyanates as Potential Electrophilic Affinity Ligands for the Brian Cannabinoid Receptor. J. Med. Chem. 1996, Vol. 39, No. 10, pages 1967-1974, see the abstract.	6 ----- 1-5, 7-14
X - Y	EP 0 471 609 A1 (GUBIN, et al)08 June 1991 (06/08/91). See the attached translated abstract and the US 5,223,510 equivalent.	1-5, 13 ----- 6

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 DECEMBER 2000

Date of mailing of the international search report

08 FEB 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
Dorthea Lawrence  
TAOFIQ A. SOLOLA

Telephone No. (703) 308-1235

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**  
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.